Community oncology teams partner with health systems to deliver advanced therapies safely, using hybrid dosing, toxicity backup, and local follow-up.
Fran Gregory, PharmD, MBA
Advertisement
Fran Gregory, PharmD, MBA, is Vice President, Emerging Therapies (Cell & Gene, Biosimilars) at Cardinal Health.
Articles by Fran Gregory, PharmD, MBA
How community oncology prepares for CAR T and gene therapy: safety gains, tech, payer shifts, and 3 must-have capabilities to expand access.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Clears Pen Device for Interferon Therapy in Polycythemia Vera
2
FDA Rejects Edotreotide PET Imaging Kit Over Manufacturing Concerns
3
Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis
4
FDA Accepts RP1 BLA Resubmission for Advanced Melanoma
5